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A 48-year-old man presented with recurrent nephrolithiasis. He had
passed two stones over the past seven years; a stone passed three years ago
required ureterolithotomy. At that time, the serum calcium was 10.6 mg/dl
(normal, 8.8—10.6 mg/dl) and the serum phosphorus was 2.9 mgldl
(normal, 2.5—4.5 mg/dl). Crystallographic analysis of that stone showed
that it contained a predominance of calcium oxalate with a small amount
of calcium phosphate. Since then the patient has generally felt well while
taking no medications. He had noticed that he had been drinking more
water over the previous few months and had had occasional nocturia. He
had no family history of nephrolithiasis.
On physical examination he was alert and in no distress. Weight was 75
kg; blood pressure, 145/92 mm Hg; the rest of the examination was
unremarkable. Serum chemistries were: calcium, 11.1 mg/dl; phosphorus,
3.2 mg/dl; alkaline phosphatase, 75 U/liter (normal, 15—95 U/liter); BUN,
15 mg/dl; creatinine, 1.0 mgldl; uric acid, 7.5 mg/dl (normal, 2.6—8.1
mg/dl); sodium, 139 mEq/liter; potassium, 4.1 mEq/iiter; chloride, 102
mEq/litcr; and bicarbonate, 25 mEq/iiter. A 24-hour urine eollection
revealed a total volume of 2750 ml; ereatinine clearance, 80 mI/mm;
calcium, 350 mg/day; and uric acid, 600 mg/day (normal, < 750 mg/day).
The serum intact PTH was 70 pg/ml (normal, 10—55 pg/mI), 25-hydroxyvi-
tamin D was normal, and serum l,25(OH)2D was 65 pg/mi (normal, 10—60
pg/mi). Maximal urinary concentration after overnight water deprivation
was 550 mOsm/kg H20. An adenoma weighing 2 g was removed from the
right parathyroid gland.
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Brigham & Women s Hospital, and Professor of Medicine, Harvard
Medical School, Boston, Massachusetts, USA): In addition to
providing a new target for the development of pharmaceutical
agents that could be effective in altering PTH secretion, the
molecular cloning of the extracellular Ca24 -sensing G-protein-
coupled receptor from parathyroid, kidney, and brain (variously
referred to as BoPCaR, RaKCaR, HuPCaR, HuKCaSR, and
CaSR), which will be abbreviated in this discussion to CaR [1—6],
has significantly expanded our understanding of calcium and
magnesium metabolism. New insights into the roles played by this
receptor in several organs, including kidney and brain, soon will
be forthcoming. Some of this new information may well suggest
hitherto unsuspected roles for the CaR and extracellular Ca2 in
the various functions of these organ systems. In this discussion, I
will focus on the proposed function of the CaR in Ca2, Mg2,
and water metabolism. Today's patient, who had primary hyper-
parathyroidism, illustrates some of the effects that increases in
extracellular calcium can have on renal function [see Refs. 7, 8 for
reviews].
The kidney provides the major route for mineral ion excretion
from the body by adjusting the tubular reabsorption of divalent
cations from the glomerular filtrate. The kidney therefore plays a
key role in Ca2 and Mg2 homeostasis. The cellular mechanisms
mediating mineral ion transport across nephron segments from
proximal tubule to collecting duct have been reviewed elsewhere
[9, 10] and will not be covered here in detail. Traditional views of
renal mineral ion handling have focused on the important roles
played by the calciotropic hormones, PTH and calcitonin, as well
as vitamin D [9, 11—16]. As discussed by Kurokawa in a previous
Nephrology Forum a decade or so ago [16], urinary calcium
excretion [Ua] increases steeply when circulating Ca2 concen-
trations [PaI rise beyond a certain threshold (Fig. 1; see Ref. 16
for a recent review). The inverse sigmoidal relationship between
increasing extracellular Ca2 and PTH secretion from parathy-
roid cells is also quite steep; this relationship suggests the possible
cooperative interactions of three or more Ca2 ions with the
cation-sensing mechanism [8]. Both PTH and vitamin D are
important modulators of the relationship between Uaand RCa,
and the absence of either calciotropic factor (or both) significantly
shifts the threshold (or "set point") for the curve to the left, such
that urinary Ca2 loss is observed at lower circulating Ca2
concentrations (Fig. 1) [11]. The steepness of the relationship
between Ua and Ca is not lost, however, even when both PTH
and vitamin D are absent. This relationship indicates that one or
more additional factors contribute to renal Ca2 excretion (Fig.
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Fig. 1. Relationship between urinaty Ca2 excretion and total serum Ca2
concentration. Urinary Ca2 increases steeply in proportion to serum Ca2
beyond a threshold concentration. The curves in the presence (solid line)
or absence (dashed line) of the calciotropic factors vitamin D and PTH are
shown. Note that absence of either calciotropic factor shifts the set point
to the left without affecting the slope of the curves. (Adapted from Ref.
16.)
1). As I will discuss in this Forum, recent evidence suggests that
extracellular Ca2 itself, interacting with the newly cloned CaR in
the kidney, provides a major part of this regulatory function.
The CaR plays crucial roles in regulating renal divalent mineral
transport processes by both direct and indirect mechanisms.
Parathyroid cells recognize remarkably small perturbations in the
circulating concentration of Ca2 (or Mg2) and then respond by
altering the secretion of PTH. In fact, most of the "sensing" of
extracellular Ca2 in parathyroid cells occurs over changes in free
Ca2 concentration of approximately 0.25 mM; that is, PTH
secretion versus [Ca2 10 is quite steep, with a K112 1.2 mM; [81.
Recent molecular and genetic evidence has demonstrated that the
cloned CaR, which is expressed on the surface of parathyroid
cells, provides the principal mechanism for extracellular Ca2
"sensing" by the parathyroid gland [reviewed in Ref. 171. In turn,
PTH modulates the renal reabsorption of Ca2' and Mg2 as well
as P043. Thus the CaR, by providing a sensor for extracellular
Ca2-mediated modulation of calciotropic hormones, indirectly
regulates renal divalent mineral handling. Moreover the kidney,
like the parathyroid, is able to respond directly (that is, indepen-
dently of changes in calciotropic hormones) to alterations in
extracellular Ca2 (or Mg2) with the resultant modulation of
mineral ion transport [see Refs. 8, 18—21 for reviews]. The cloning
of the CaR from rat [2] and human [5] kidney and the expression
of the CaR in renal epithelial cells [221 is consistent with a
mechanism whereby extracellular calcium participates directly in
the regulation of its own reabsorption through local, receptor-
mediated actions of Ca2 (and/or Mg2) on the kidney. Evidence
supporting this view will be described in the following sections.
The homeostatic adjustments in urinary excretion of mineral
ions provided by calciotropic factors (mainly PTH and vitamin D)
and the CaR are not without potential consequences on renal
function. With increased loads of calcium (for example, from
enhanced bone turnover or absorption from the intestinal tract, or
from abnormalities of mineral ion reabsorption along the
nephron), urinary calcium excretion can increase dramatically
(Fig. 1). The continued formation of a concentrated urine during
periods of increased urinary Ca2 or Mg2 loss could present a
problem, because mineral ions can reach supersaturation levels in
the terminal collecting duct; this supersaturation in turn increases
the risk of nephrolithiasis, nephrocalcinosis, or both. Recently we
have suggested that a "trade-off" of water conservation for Ca2
or Mg2 loss operates to minimize the risk of stone formation
under normal circumstances, especially during periods of in-
creased mineral ion excretion [23]. The renal CaR appears to
provide the crucial "sensing" mechanism in the distal nephron and
collecting duct for integrating and balancing water and divalent
mineral loss. Direct interactions of extracellular Ca2 with the
renal CaR could explain in large part the disordered water
metabolism (that is, nephrogenic diabetes insipidus) observed
during pathologic states of hypercalcemia (for example, primary
hyperparathyroidism or certain malignancies) [24, 25].
The extracellular Ca2 tsensing receptor
Extracellular Ca2 modulates both PTH secretion and renal
tubular divalent mineral and water transport processes by inter-
acting with a specific receptor, the CaR. A wealth of indirect
evidence has suggested the existence of a Ca2-responsive, recep-
tor-like mechanism in parathyroid cells; for instance, raising
extracellular Ca2 activated a number of second messenger
systems in a fashion similar to that for other G-protein-coupled
receptors, for example, activation of phospholipase C (PLC) with
consequent accumulation of inositol 1,4,5-trisphosphate (1P3) [26]
and release of Ca2 from intracellular stores [27] [see Refs. 7, 8,
18 for reviews]. Moreover, second messenger systems in several
nephron segments also are modulated by changes in extracellular
Ca2 [28—32]. The ability to express exogenous receptors in
oocytes of the frog Xenopus laevis, and then to detect function of
phosphoinositide (P1)-coupled receptors through electrophysi-
ologic measurement of intracellular Ca2-activated chloride
channels, enabled Brown and coworkers to clone the complemen-
tary DNA (eDNA) encoding the Ca2-sensing receptor from
bovine parathyroid gland (BoPCaR) [1]. Subsequently, this recep-
tor also was cloned from human parathyroid [3], rat [2] and
human [5] kidney, and rat brain [4]. When these receptors were
expressed in oocytes (by injecting the oocytes with synthetic
mRNA transcribed from the cloned cDNAs), they behaved like
the native Ca2-sensing receptor of the parathyroid gland [1—3]:
the cloned CaR was activated by the same di- and trivalent cations
and even polycations (for example, neomycin) as the native
receptor [33—36]. This CaR represents the first example of a
G-protein-coupled, cell-surface receptor in mammalian species
that recognizes an inorganic ion rather than a molecule as its
ligand [37J. The availability of these cloned genes and of antibod-
ies against the receptor (produced from knowledge of the de-
duced amino acid sequences of the receptor proteins) has permit-
ted studies of receptor localization, function, and regulation as
well as identification of mutations of this receptor that produce
inherited disorders of calcium metabolism. Much of this work is in
progress, and over the next few years we can expect additional
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Fig. 2. Topologic features of the predicted CaR. Symbols are given in the key. Locations of known "inactivating" (x) and "activating" (*) mutations are
indicated.
information, as well as probably some surprises, on the roles of
this receptor in endocrine glands, kidney, intestine, brain, and
possibly other tissues and cells [see Refs. 23, 381.
As expected, the deduced amino acid sequence of the CaR
shows the classic seven-transmembrane-spanning helical domain
thus far found on all G-protein-coupled receptors (GPRs; Fig. 2)
[39, 40]. The CaR is a novel receptor, however, in that it has a
significant (hut low) amino acid sequence similarity only with the
G-protein-coupled (metabotropic) glutamate receptors, mGluRs,
expressed in the central nervous system [41]. Conklin and Bourne
have suggested that the extracellular ligand-binding domains of
the CaR and the mGluRs have an overall structural organization
[37] similar to that of bacterial periplasmic nutrient-binding
proteins [42, 43]. These bacterial cell-surface proteins bind a
variety of extracellular solutes (thus enabling cellular uptake),
including organic nutrients as well as inorganic ions such as
phosphate and nickel [43]. Thus the extracellular Ca2-sensing
receptor might have evolved from an ancient family of cell-surface
proteins binding essential extracellular solutes. This similarity also
suggests the possibility of additional ion (solute)-sensing recep-
tors.
The pharmacology of this CaR is unusual for a GPR in that it
responds to its natural ligand, in this case Ca2 (and Mg2), only
in the millimolar ion concentration range (recall that the phar-
macologically relevant concentrations of other first messengers
are usually in the picomolar to micromolar range). The former,
however, is the physiologically relevant Ca2 concentration range
(0.75—2.0 mM free Ca2) for extracellular fluid, as opposed to the
Ca2 cytosolic range [10_9_10_6 MI. In this regard, the large
extracellular domain does not exhibit any of the known high-
affinity Ca2-binding motifs. Instead it contains several regions
rich in negatively charged (acidic) amino acids that probably
mediate the low-affinity binding of cationic receptor agonists (for
example, Ca2, Mg2, Gd3, neomycin) in a fashion similar to the
acidic domains found on low-affinity calcium-binding proteins
such as calsequestrin [44]. These negatively charged sites could
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bind multiple Ca2 ions on each receptor molecule, which might
provide for cooperative cation interactions and the steep activity
curve (Fig. 1).
Inherited human diseases of extracellular Ca2 sensing
Elimination of a gene (and therefore the function of the protein
encoded by the gene) through gene "knockouts," or overexpres-
sion of genes via production of transgenic animals, has provided
powerful tools for defining the biologic role of a variety of genes.
In certain cases, human genetic diseases have yielded examples of
naturally occurring "knockouts" or "transgenics" by exhibiting
mutations that inactivate or activate, respectively, the gene itself
or the function provided by the encoded protein. Indeed, the
clinical and physiologic relevance of the CaR has been established
by the demonstration that mutations in it cause three inherited
diseases of calcium metabolism. Two rare hypercalcemic disor-
ders, familial hypocalciuric hypercalcemia (FHH) [45, 46] and
neonatal severe hyperparathyroidism (NSHPT) result from inac-
tivating mutations [47] when present in the heterozygous and
homozygous ("knockout" equivalent) states, respectively [481.
One form of an autosomal dominant hypocalcemia [91 also
results from a mutation in the CaR gene [50] and leads to
expression of an overactivated receptor ("transgenic" equivalent).
The FHH gene had already been localized to the long arm of
chromosome 3 in most [51, 52] but not all [51—541 families with
FHH and NSHPT when the CaR was cloned. This CaR was an
obvious candidate gene for FHH. Indeed, Pollak and coworkers
demonstrated that the CaR gene mapped to the FHH disease
locus and that point mutations (that is, single base changes) within
this receptor gene were responsible for FHH in three families
[47]. Other groups subsequently confirmed these results [54—56].
Mutations are scattered throughout the predicted protein (Fig. 2)
[47, 55, 56] and apparently modify the structure and/or ligand-
binding properties of the CaR. In one family, the mutation
produces a stop codon that results in translation of a truncated
and presumably biologically inactive receptor (Fig. 2) [56]. The
genes involved in the families with the FHH phenotype not
mapping to chromosome 3q arc unknown [54].
In accord with the genetics, in-vivo and in-vitro studies have
shown abnormal parathyroid and renal Ca2 sensing in FHH and
NSHPT. Parathyroid cells either show reduced sensitivity (FHH)
or lack any PTH secretion responses (NSHPT) to increases in
extracellular Ca2 [57—59]. Abnormal renal Ca2 sensing is
suggested by the finding that, despite hypercalcemia, individuals
with these disorders have reduced fractional renal clearance of
Ca2 and Mg2 [45, 46, 60] and often exhibit frank hypocalciuria,
that is, well under 100 mg/day. Moreover, individuals with FHH or
NSHPT who have had parathyroidectomy, and thus have reduced
or absent circulating PTH, continue to show markedly reduced
renal calcium clearance, even during the intravenous infusion of
sufficient calcium to induce frank hypercalcemia [601. Figure 3
illustrates a comparison of urinary calcium (U) as a function of
serum calcium levels (a) in hypoparathyroid "normal" and
FHH individuals. Another feature of hypoparathyroid FHH
shown in Figure 3 is the complete loss of the steep relationship
between and Ca (compare Figs. 1 and 3 and note that the
curve is almost flat in the FHH individuals). These studies clearly
demonstrate that the hypocalciuria observed in hypercalcemic
FHH is PTH independent and secondary to an intrinsic alteration
in renal handling of Ca2 somewhere along the nephron. More
Serum Ca2 (mg/dI)
Fig. 3. Effect of calcium load on urinay calcium excretion in hypoparathy-
roid FHH patients (A) and hypoparathyroid controls (LI) during infusions of
calcium. Urinary excretion of calcium is plotted as a function of total
serum Ca2 concentration. In the subjects receiving calcium infusion,
creatinine clearance did not change during the study. The solid line and
dashed lines represent mean and 95% confidence intervals, respectively,
from normoparathyroid control individuals. (Adapted from Refs. 60 and
90.)
than a decade ago, Attic et al suggested a defect in the ascending
limb of the ioop of Henle, because people with FHH exhibited an
exaggerated calciuric response to the loop diuretic ethacrynic acid
[60]. This response is consistent with the hypothesis that the CaR,
which is decreased in FHH, influences Ca2 reabsorption in the
thick ascending limb (Fig. 4).
The renal clearance of Mg2, like that of Ca2, also is reduced
in patients with FHH, and some individuals with NSHPT have
overt hypermagnesemia even with a normal creatinine clearance
[45, 46]. This finding suggests that the CaR in kidney also
functions as a Mg2 sensor. The apparent affinity of the CaR for
Mg2, however, is too low for normal variations in the circulating
Mg2 concentration to influence this receptor [81. Nevertheless, it
is possible that the basolateral concentration of Mg2', to which
the receptor might be exposed in the thick ascending limb (where
Ca2 and Mg2' regulate their own reabsorption [10, 20, 61] and
where both Ca2 and Mg2 are reabsorbed [10, 62] in the absence
of water [63]), is actually higher than that in blood. In this regard,
Attic and colleagues found that hypoparathyroid individuals with
FHH and NSHPT exhibited a reduced Mg2 clearance compara-
ble to the reduced clearance observed for Ca2 [60].
Finally, unlike patients with hypercalcemia due to other causes,
who commonly develop an ADH-resistant polyuria [25, 64—68],
hypercalcemic individuals with FHH do not have polyuria and
show normal maximal urinary concentrating ability after dehydra-
tion [24]. Their Ca2 "resistance," which results from a reduced
number of normal Ca2-sensing receptors, clearly diminishes the
impact of hypercalcemia on loop of Henle or collecting duct
functions, which are responsible for water handling.
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Fig. 4. Model for the role of the extracellular Ca2 -sensing receptor in the regulation of NaC1 and Ca2 (Mg2) reabsorption in the thick ascending limb(T.4L). Increases in peritubular Ca2 activate the CaR and reduce hormone-stimulated cyclic AMP production, which reduces net NaCI absorption and
the lumen-positive transepithelial voltage, V,. Activation of the CaR also reduces activity of the apical K channels and thereby reduces potassium
recycling. The net effect of both CaR-mediated processes is a reduction in divalent mineral (Ca2 and Mg2) transport (reabsorption) via the
paracelhilar pathway.
CaR in the kidney
The Ca2-sensing receptor has been localized within several
segments of the rat nephron that subserve functions that are
directly regulated by extracellular calcium. The receptor is most
heavily expressed in the cortical thick ascending limb but also is
present in the proximal tubule, medullary thick ascending limb,
distal convoluted tubule, and along the entire collecting duct ([2],
Riccardi D, unpublished observations). Previously described ef-
fects of extracellular Ca2 ' (and Mg2) on these segments of the
nephron include the following: inhibition of the 1-hydroxylation of
25-hydroxyvitamin D in the proximal tubule independent of PTH
[69, 70; see Refs. 7,8 for discussions]; inhibition of NaC1 transport
in the thick ascending limb [68]; reduction in Ca2 and Mg2
reabsorption in the medullary thick ascending limb [10, 20, 21, 61,
71, 72]; pertussis-toxin-sensitive decrease in hormone-stimulated
cAMP accumulation in the medullary thick ascending limb and
cortical thick ascending limb [29, 31, 73]; inhibition of ADH's
action in the collecting duct [28, 32, 74]; and the direct effect of
Ca2 on calbindin-D25k mRNA in the distal convoluted tubule
(DCT) [75]. Studies are currently underway in several laboratories
to assess the role of the CaR as the mediator of the effects of
extracellular Ca2 on several aspects of renal function.
The model for the thick ascending limb shown in Figure 4
proposes that elevated levels of pcrituhular Ca2 (or Mg2)
reduce NaCl reabsorption and the magnitude of the transepithe-
hal voltage, and hence Ca2 and Mg2 reabsorption, via a
Ca2 -sensing, receptor-dependent mechanism. In the thick as-
cending limb (TAL), the lumen positive potential, Vte, is the
driving force for Ca2 and Mg2' transport via the paracellular
pathway [76—79]. In turn, V is directly related to the magnitude
of net NaC1 absorption [63], which is stimulated by the integrated
action of several hormones including ADH and the calciotropic
hormones PTH and calcitonin [62, 63, 80]. Preliminary results
from my own laboratory suggest that the CaR is expressed on
basolateral membranes of TAL cells (unpublished observations).
Thus peritubular Ca2-mediated activation of the CaR could
influence divalent mineral reabsorption either by reducing hor-
mone-stimulated cyclic AMP production or by directly modulat-
ing the activity of the salt transporters themselves. In fact,
increases in extracellular Ca2 ' mediate pertussus-toxin-sensitive
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Fig. 5. Role of the extracellular Ca2 '-sensing receptor in the regulation of water reabsorption in the terminal collecting duct. Peritubular Ca2 can influence
ADH-stimulated cAMP production. In addition, luminal Ca2 reduces ADH's ability to stimulate the activity of aquaporin-2 (APQ2) water channels
in the apical membrane. The net effect of these CaR-mediated processes is a reduction in ADH-stimulated water permeability of the collecting duct.
reductions in cyclic AMP generated by these hormones [29, 31,
73], and the CaR likely mediates this effect. Could extracellular
Ca2 via the CaR also modulate any of the transporters involved
in NaCI absorption by the TAL? This possibility was recently
examined by Wang and coworkers [81, 821, who assessed the
effects of extracellular Ca2 on the 70 pS inwardly rectifying K
channel, which provides the major apical membrane potassium
permeability of TAL cells [83]. Recycling of K via this channel
not only supplies cation for Na-K-2Cl cotransport but also is
crucial to the generation of Vte [63, 83]. Wang et al showed that
increasing extracellular Ca2 (as well as neomycin, a polyvalent
organic cation that is a potent agonist of the CaR [1, 2, 8])
reversibly reduced K channel activity via a P450 oxygenase
metabolite [82]. This reduction in the apical K conductance of
the TAL would be expected to reduce both NaCI and Ca2 (or
Mg2) reabsorption and markedly increase urinary Ca2 excre-
tion similar to that which occurs with the administration of
furosemide [84, 851.
It is also possible that extracellular Ca2 might modulate NaCI
and/or Ca2 transport in the DCT during hypercalcemia via a
direct interaction of extracellular Ca2 with the Ca2-sensing
receptor. Thiazide-type diuretics, which block the apical Na-Cl
cotransporter in the DCT, dissociate Na and Ca2 reabsorption
by this nephron segment [86, 87]; this dissociation has been
attributed to effects of cellular Na uptake on either cellular Ca2
entry [881 or exit [86] mechanisms. This inverse relationship
between Ca2 and Na transport in DCT cells [88, 89] could
account for reduced Ca2 reabsorption by the DCT during
hypercalcemia. In other words, the increased delivery of Na to
the DCT from the TAL would tend to decrease the ability of the
DCT to reabsorb Ca2 and hence help promote the calciuria.
Clearly, this issue requires further study.
Several studies also suggest a potential role for the CaR in
water handling by the collecting duct. These actions are depicted
in Figure 5. Previous studies had suggested an effect of peritubular
Ca2 on modulating vasopressin-stimulated increases in water
permeability of the cortical collecting duct [28, 32]. Moreover, a
recent preliminary study also suggests an important role for
tubular urine Ca2 concentration in regulating the water perme-
ability of the inner medullary collecting duct (JMCD) from rat
kidney [71. Baum and colleagues have shown that the CaR and
aquaporin-2 co-localize to apical membranes of the IMCD and
that raising the Ca2' concentration in tubular fluid reversibly
reduces the magnitude of ADH-stimulated water permeability of
this terminal nephron segment. Thus, in the collecting duct there
may be a Ca2-sensing function via the CaR from both basal
(interstitial or circulating) and tubular urinary sides. More studies
of the effects of extracellular Ca2 on water and other solute
transport mechanisms in the collecting duct are required before
we can fully understand the extent of the regulatory roles played
by the CaR in these processes.
Summary of the integrated effects of the CaR on divalent mineral
and water excretion
Let me summarize the proposed role of the renal extracellular
Ca2-sensing receptor in integrating divalent mineral and water
handling by the kidney (Fig. 6). The net effect of increased
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Fig. 6. Proposed central role of the renal extracellular
Ca2 tsensing receptor (CaR) in integrating divalent
mineral and water handling by the kidney. With
physiologic transient hypercalcemia, this CaR-mediated
reduction in concentrating ability would provide a
regulatory mechanism ensuring that the increased
delivery of Ca2 and Mg2 from the thick ascending
limb (TAL) to the collecting duct would be excreted in
a more dilute urine, thereby decreasing the risk of
crystal/stone formation. A similar mechanism could
account for the nephrogenic DI commonly observed in
patients with pathologic or chronic hypercalcemia.
basolateral (peritubular) Ca2 on the TAL is a "loop"-diuretic-
like action. This effect not only would reduce NaC1 reabsorption
and hence countercurrent multiplication, but also would decrease
the lumen-positive Vte in TAL, which is the driving force for Ca2
and Mg2 transport via the paracellular pathway. An increased
load of Ca2 (and/or Mg2) then would be delivered to the
collecting duct. Direct effects of extracellular Ca2, acting via the
CaR to reduce the ADH-stimulated water permeability of the
collecting ducts would add further to the reduction in urine
concentration brought about by effects of extracellular Ca2 in the
TAL. Particularly important would be the potential direct influ-
ence of the tubular urine Ca2 concentration itself, as it would
help to integrate directly changes in distal Ca2 delivery with the
magnitude of water reabsorption in the terminal collecting duct.
Thus the kidney has a built-in divalent mineral regulatory mech-
anism (that is, the CaR) that helps ensure that Ca2 and Mg2 are
excreted at concentrations below saturation. During pathologic or
chronic hypercalcemia this mechanism could account for the
nephrogenic diabetes insipidus commonly seen with this electro-
lyte disorder [25]. As demonstrated by the case presentation,
despite this integrated mechanism, stone formation still occurs
under certain circumstances.
Questions and answers
DR. NICOLAOS E, MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Two other cat-
ions that come to mind in terms of possible interaction with the
Ca2-sensing receptor are lithium and aluminum. Lithium is a
monovalent cation that occasionally leads to hyperparathyroid-
ism. On the other hand, in-vitro work indicates that aluminum, a
trivalent cation, inhibits PTH release from parathyroid cells, and
aluminum-related bone disease is often associated with decreased
PTH. Do these cations bind to the receptor?
DR. HEBERT: Ed Brown showed years ago that lithium induces
abnormal calcium-regulated release of PTH from dispersed bo-
vine parathyroid cells. Since the calcium-sensing receptor mcdi-
ates the regulation of PTH secretion, when you reduce calcium
sensing, PTH secretion increases and hyperparathyroidism re-
sults. Some patients on lithium will have a disease like primary
hyperparathyroidism, which is most often reversible by eliminat-
ing the lithium. In some limited studies we've begun to look at
that. It's not surprising that monovalent cations have some effects
on this calcium sensor. The binding of calcium to the receptor is
thought to involve acidic negatively charged amino acids mainly
located in the large extracellular domain, and other cations could
alter calcium-binding interactions.
DR. MADIAS: Isn't it somewhat surprising that a system like
calcium homeostasis that is so tightly regulated would have a
receptor recognized by several ligands other than Ca2 and
exhibiting such a substrate promiscuity?
DR. HuBERT: The promiscuity may be a consequence of physi-
ologically appropriate millimolar affinity of this receptor for
calcium. This sensor responds to small variations in calcium in a
virtual "sea" of calcium (and other ions). If it were a high-affinity
calcium ion receptor, all calcium-binding sites would be fully
saturated at normal circulating calcium concentrations, and the
receptor would be continuously activated and unaffected by
changes in circulating calcium. Multiple (low-affinity) calcium-
ion-binding sites may function in a cooperative fashion to account,
at least in part, for the steep relationship between extracellular
ionic calcium and PTH release or renal calcium excretion. The
nature of the calcium-binding sites thus might account for the
ability of other ions to interact with these sites. Consequently,
other cations (inorganic ions or organic drugs) could interfere
with calcium sensing.
DR. BESS DAWSON-HUOHES (USDA Human Nutrition Research
Center on Aging, Tufts University School of Medicine, Boston): Do
you believe that the calcium sensor has anything to do with the
hypertension that is associated with hyperparathyroidism?
DR. HEBERT: That's an interesting question, but we don't have
an answer for it. If we had to speculate, one of the areas we would
offer as playing a potential role would be the effects of the
2136 Nephrology Forum: Extracellular calcium-sensing receptor
receptor in the central nervous system. I discussed one locus, the
subfornical organ, but the receptor is also expressed in other
regions of the brain. Could there be a role for the calcium
receptor in the central regulation of blood pressure? It would be
premature to speculate too much other than to say that it's
possible that there could be many effects of calcium on brain and
possibly vascular function. Some of these cells might be respond-
ing to local changes in calcium that may be related to neuronal
activity. Local changes in calcium could provide important signals
to groups of functioning neurons in the central nervous system,
including those involved in blood pressure control.
DR. JEFFREY TATRO (Division of Endocrinology, New England
Medical Center): Is there evidence for other variants of the
receptor, or is there only a single gene?
DR. HEBERT: So far, we think it's a single gene. There is another
potential calcium-sensing molecule that has been identified by
Lundgren et al, which is a member of the LDL receptor family, a
GP330-like molecule that is quite interesting [91]. It's clear that
from the FFH-NSHPT studies that the receptor that we have
cloned is the primary sensor in the parathyroid gland. This does
not exclude the possibility that associated molecules or other
receptors can modulate (or provide) ion sensing in certain other
tissues. We certainly can't exclude the possibility that other genes
are involved in ion sensing. One could postulate sensors for
potassium, phosphate, sodium, or protons, for example. Another
aspect of this that makes such a speculation rational is the fact
that if one looks at the potential structure of the extracellular
domain, one can find a similarity between the extracellular
domain of the metabotropic glutamate receptors and the calcium-
sensing receptor. Several investigators have studied the structural
homologies of the extracellular domain with other proteins. They
identified significant similarities between the extracellular domain
of the metabotropic glutamate receptors and a group of proteins
that are called periplasmic nutrient-binding proteins found in
bacteria with cell walls. These small molecules, many of which
have been crystallized, have known structures. These proteins are
free-floating in the periplasm between the bacterial cell mem-
brane and the cell wall. As nutrients enter through pores in the
cell wall, these specific proteins bind these nutrients and complex
with bacterial permeases. The latter provides for transport of the
nutrient into the bacterial cell. Many different bacterial nutrient-
binding proteins are known, and several of the nutrients include
ions. Thus, if these proteins and the calcium-sensing receptor have
a common evolutionary origin, there could exist receptors in
humans for other ions or nutrients.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): A frequent clinical finding in patients who are
hypercalcemic is severe volume depletion. Do you think the
mechanism by which that occurs relates to inhibition of the
potassium channel by the calcium receptor?
DR. HEBERT: Yes, we think that the calcium receptor will be
proven to be a major regulator of salt, as well as of divalent
mineral reabsorption, in the thick limb. Calcium-mediated activa-
tion of the receptor leading to inhibition of the apical potassium
channel would produce an effect similar to the response to
furosemide on thick limb function. To that extent, the patient
would lose sodium. In fact, one can detect small increases in
sodium excretion with transient hypercalcemia.
DR. KiNG: Is the receptor sensitive to monovalent cations such
as sodium?
DR. HEBERT: Probably. As I said earlier, we expect that a
number of monovalent ions alter calcium ion interactions with the
receptor.
DR. MADIAS: In vitro, dispersed parathyroid cells exhibit sub-
stantial heterogeneity in their PTFT response to changes in the
Ca2 concentration of the medium [92, 93]. Is it known whether
the Ca2-sensing receptor is involved in this variability, for
example due to different complement of receptors?
DR. HEBERT: You do see differences in staining among groups
of cells in the parathyroid. This is particularly prominent if one
looks at parathyroid tissue from primary and uremic secondary
hyperparathyroidism [1• In secondary hyperparathyroidism, the
gland contains what looks like islands of cells that have a normal
amount of receptor surrounded by many cells with a very low
complement of receptor; this finding probably reflects the clonal
nature of the cellular hypertrophy.
DR. AJAY K. SINGH (Division of Nephrology, New England
Medical Center): You suggested that activation of the calcium-
sensing receptor due to high prevailing plasma levels of calcium
and/or magnesium modulates urinary excretion of the corre-
sponding divalent cation. Could you elaborate on calcium-sensing
receptor function when there is hypocalcemia with a normal, or
perhaps even an elevated, magnesium level or the converse, a low
magnesium level with a normal calcium?
DR. HEBERT: That's an important question. As I discussed, it
takes a much higher concentration of magnesium than calcium to
activate the receptor. That partially answers the question you
asked, but it raises an additional question: is this receptor a
magnesium sensor, at least in certain tissues? Can the calcium
receptor sense normal concentrations of magnesium in the kid-
ney? Quamme and others have shown over the last two decades
that, in the thick ascending limb, hypermagnesemia in rats dra-
matically affects loop function with regard to sodium chloride
reabsorption as well as magnesium and calcium reabsorption [20,
21]. Thus extracellular magnesium is clearly involved somehow in
modulating thick ascending limb function. It is possible that in the
thick ascending limb, where calcium and magnesium reabsorption
normally occur, that is, ions moving from urinary space to the
basal side of the cell in an epithelium where there is virtually no
water movement, the calcium and/or magnesium concentration on
the basal side of the cell increases to levels that could activate or
influence the receptor. In this way, magnesium reabsorption by
the thick limb could influence both calcium and magnesium
reabsorption.
DR. MADIA5: I'm trying to think of some other clinical disorders
in which the Ca2tsensing receptor might be dysregulated. One
disorder that comes to mind is familial idiopathic hypercalciuria.
Another is Bartter's syndrome. Could you speculate on these
possibilities?
DR. HEBERT: We've thought along these lines as well and are
currently investigating the possible involvement of receptor dys-
regulation in idiopathic hypercalciuria and Bartter's. Lifton's
group at Yale has made significant advances in the identification
of genes involved in autosomal recessive forms of Bartter's
syndrome, including the Gitelman's variant of Barttcr's syndrome
[95, 96]; these forms are characterized by inherited hypokalemic
alkalosis as well as alterations in divalent mineral excretion.
Gitelman's disease is caused by mutations in the thiazide-sensitive
Na-Cl cotransporter that presumably result in loss of function
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of the cotransporter. We (unpublished observations) and Lem-
mink and coworkers [97] also have found linkage and/or muta-
tions in the thiazide-sensitive Na-CU cotransporter in other
families with the Gitelman's phenotype, thus confirming the
findings by Lifton's group. Gitelman's disease thus can be re-
garded as a dysfunction of salt transport in the distal convoluted
tubule. Individuals with Gitelman's disease are characterized by
hypomagnesemia (with hypermagnesuria) and hypocalciuria. Be-
cause Na-CL cotransporter activity presumably is reduced in
this disease, the reduced excretion of calcium can be explained by
this functional defect that mimics thiazide use. More recently
Lifton's group identified mutations in the loop-diuretic-sensitive
Na-K-2Cl cotransporter as the molecular basis of Bartter's
syndrome in certain families, whose affected members are char-
acterized by hypokalemic alkalosis, severe volume depletion, and
hypercalciuria [96]. Thus, at least in some patients with familial
Bartter's syndrome, the abnormal gene is the furosemide (bumet-
anide)-sensitive Na-K-2C1 cotransporter in the thick ascend-
ing limb of Henle (TAL), and this disease can be thought of as a
dysfunction of salt transport in the TAL. Loss of function of
Na-K-2Cl cotransport in the TAL would decrease calcium
and magnesium reabsorption and increase their loss in the urine;
this effect mimics the response to furosemide. It is possible that
mutations in other genes may be identified in other families with
the autosomal recessive form of Bartter's syndrome.
Although dysfunction in the Ca2-sensing receptor in the TAL
would be expected to alter TAL function, I think that it is unlikely
that the Ca2-sensing receptor gene is directly involved in the
molecular basis of Bartter's syndrome, because one would expect
not only abnormalities in divalent handling by the kidney but also
altered parathyroid-PTH secretory function. The potential role of
the Ca2-sensing receptor in familial idiopathic hypercalciuria is
currently under investigation.
DR. MADIAs: Is any work being done on the regulation of the
receptor, and are there any recognized hormonal effects on the
receptor?
DR. HEBERT: To date, we have not seen any effector systems
that have a significant impact or influence on receptor density.
DR. MADIAS: Is the Ca2-sensing receptor involved in other
calcium-related phenomena, such as renal hemodynamics, renin
release, calcitonin secretion, or bone resorption?
DR. HEBERT: This is a very interesting and important question.
We and others are looking at these issues, and answers may be
forthcoming.
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